Two Sigma Advisers
IPSC icon

Two Sigma Advisers’s Century Therapeutics IPSC Stock Holding History

Two Sigma Advisers’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,267,700
Closed -$1.26M – 1059
2025
Q4 		$1.26M Buy
1,267,700
+410,100
+48% +$250K ﹤0.01% 1369
2025
Q3 		$427K Buy
857,600
+490,500
+134% +$264K ﹤0.01% 1827
2025
Q2 		$205K Buy
367,100
+290,200
+377% +$156K ﹤0.01% 2116
2025
Q1 		$36.6K Buy
76,900
+25,900
+51% +$19.5K ﹤0.01% 2337
2024
Q4 		$51.5K Buy
+51,000
New +$69.4K ﹤0.01% 2280
2023
Q3 		– Sell
-15,600
Closed -$49.3K – 2479
2023
Q2 		$49.3K Sell
15,600
-12,500
-44% -$40.3K ﹤0.01% 2276
2023
Q1 		$97.5K Buy
+28,100
New +$123K ﹤0.01% 2388

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Two Sigma Advisers's IPSC Position: Q1 2026 in Review

Two Sigma Advisers sold out of Century Therapeutics (IPSC) in Q1 2026, closing a stake of 1,267,700 shares — an estimated $1.26M sold.

Two Sigma Advisers first reported a position in IPSC in Q1 2023 and held it in 7 quarters. The position peaked at $1.26M in Q4 2025. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • Two Sigma Advisers reported no remaining Century Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,267,700 Century Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Two Sigma Advisers first reported a position in Century Therapeutics in Q1 2023 and held it in 7 quarters.
  • Two Sigma Advisers's Century Therapeutics position peaked at $1.26M in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.